Showing results (101-110 of 201) with videos related to
Sort By:
Pageof 21
Thrombosis and Haemostasis|April 20, 2021
Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort StudyPhilippe Girard, Silvy Laporte, Céline Chapelle, et al.Journal of Geriatric Oncology|May 21, 2023
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 studySébastien Gendarme, Sonia Zebachi, Romain Corre, et al.Journal for Immunotherapy of Cancer|May 25, 2023
Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumorsClémence Demerlé, Laurent Gorvel, Marielle Mello, et al.JTO Clinical and Research Reports|February 3, 2022
Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical ResectionMike R Sung, Pascale Tomasini, Lisa W Le, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2025
Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II TrialOliver Gautschi, Keunchil Park, Benjamin J Solomon, et al.Annales Pharmaceutiques Francaises|October 10, 2025
The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer careFlorence Ranchon, Florian Slimano, Maha Ayyoub, et al.Clinical Lung Cancer|February 17, 2019
Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung CancerPascale Tomasini, Celine Mascaux, Kevin Jao, et al.JTO Clinical and Research Reports|September 30, 2021
Development and Validation of a Simplified Prognostic Score in SCLCElodie Negre, Amandine Coffy, Alexandra Langlais, et al.The European Respiratory Journal|May 24, 2020
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trialArmelle Lavole, Laurent Greillier, Julien Mazières, et al.The Lancet. Respiratory Medicine|November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 studyHervé Léna, Laurent Greillier, Claire Cropet, et al.Pageof 21